在心力衰竭中使用SGLT2抑制剂和左心房功能,心脏衰竭的排泄分数减少或轻微减少
Hakan Duman1, Hüseyin Durak2, Mustafa Çetin1
1Department of Cardiology, Faculty of Medicine, Recep Tayyip Erdoğan University, Rize, 53100, Türkiye.
BMC cardiovascular disorders
|November 14, 2025
概括
-葡萄糖共传输体-2 (SGLT2) 抑制剂在心力衰竭 (HF) 患者中没有改善左心房 (LA) 功能,心脏衰竭患者的排泄分数 (EF) 减少. 腹腔动脉的结构和功能主要受到透缩功能障碍和心室重塑的影响,而不是SGLT2疗法.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- -葡萄糖共运输体-2 (SGLT2) 抑制剂是心力衰竭 (HF) 的确立治疗方法,减少死亡率和住院治疗.
- SGLT2 抑制剂对左心房 (LA) 结构和功能在低或轻微降低射出分数 (EF) 的HF 患者的影响尚不清楚.
研究的目的:
- 研究SGLT2抑制剂对左心房 (LA) 结构和功能在心力衰竭 (HF) 和减少或轻微减少喷射率 (EF) 的患者的影响.
主要方法:
- 一项观察性,横截面研究涉及134名HF患者,EF<50%,分为SGLT2抑制剂使用者 (SGLT2+) 和非使用者 (SGLT2-).
- 心声学测量包括LA体积指数 (LAVI),LA排空分数 (LAEF) 和LA功能指数 (LAFI).
- 对比了临床,实验室和心声学参数,并使用多变量线性回归分析了与LA指数的相关性.
主要成果:
- 在SGLT2+组中,糖尿病发病率较高,螺旋乳和furosemide使用率较高.
- 在SGLT2+组中观察到左下心室喷射分数 (LVEF) 和较大的左心室体积.
- 在SGLT2+组中发现LA功能指数 (LAFI) 显著下降,但在LAVI或LAEF中没有观察到群体之间的显著差异.
结论:
- 使用SGLT2抑制剂与降低或轻微降低EF的HF患者的LA体积或功能参数的改善无关.
- 功能的预后价值主要与腹功能障碍和心室重塑有关,而不是SGLT2抑制剂治疗.
更多相关视频
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
7.0K
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.9K
相关概念视频
01:30Heart Failure V: Medical Management
207
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
207
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
902
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
902
01:22Heart Failure VI: Adjunct Therapies
243
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
243
01:22Heart Failure Drugs: Diuretics
779
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
779
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
01:22Heart Failure Drugs: β-Blockers
747
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
747